51 results found.

Chronic Hepatitis C, Hepatitis C Virus, or Compensated Cirrhosis Clinical Trial using ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

AbbVie - Recruiting 18 years to 70 years.
- A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

Primary Biliary Cirrhosis Clinical Trial using LUM001; Placebo; Ursodeoxycholic Acid

Lumena Pharmaceuticals, Inc. - Recruiting 18 years to 80 years.
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis.
LUM001; Placebo; Ursodeoxycholic Acid

Cirrhosis of Liver, or Hepatic Encephalopathy Clinical Trial using L-ornithine L-aspartate; Placebo

Dayanand Medical College and Hospital - Recruiting 18 years to 70 years.
- Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial.
L-ornithine L-aspartate; Placebo

Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirr Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure.
IDN-6556

PBC Clinical Trial using Bezafibrate; placebo

Assistance Publique - Hôpitaux de Paris - Recruiting 18 years to 69 years.
- Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy..
Bezafibrate; placebo

Cirrhosis Clinical Trial using Terlipressin; Placebo

Assistance Publique - Hôpitaux de Paris - Recruiting 18 years or older.
- Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study.
Terlipressin; Placebo

Status; Splenectomy Clinical Trial using Desflurane; Propofol

Theodor Bilharz Research Institute - Recruiting 25 years to 55 years.
- Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis..
Desflurane; Propofol

Alcoholic Cirrhosis Clinical Trial using Zinc; Placebo

University of Louisville - Recruiting 18 years to 75 years.
- A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis.
Zinc; Placebo

Compensated Alcohol-related Cirrhosis and Portal Hypertension Clinical Trial using Terlipressin acetate; Serelaxin (RLX030)

Novartis - Recruiting 18 years to 75 years.
- An Exploratory Study to Investigate the Haemodynamic Effects of Serelaxin (RLX030) in Patients With Compensated Cirrhosis and Portal Hypertension.
Terlipressin acetate; Serelaxin (RLX030)

Cirrhosis Clinical Trial using rifaximin

Shanghai Changzheng Hospital - Recruiting 18 years to 75 years.
- Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial.
rifaximin

Liver Diseases, Hepatocellular Cancer, Endstage Liver Disease, or Clinical Trial using donor pain management/ Pre-operative OR Set-up

Northwestern University - Recruiting 21 years to 60 years.
- A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant.
donor pain management/ Pre-operative OR Set-up

Liver Cirrhosis, or Portal Vein Thrombosis Clinical Trial

Beijing Friendship Hospital - Recruiting 18 years to 80 years.
- Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis.

Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area.

Primary Biliary Cirrhosis Clinical Trial using Genetic Analysis

Mayo Clinic - Recruiting 18 years to 90 years.
- Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC)..
Genetic Analysis

Ascites, or Cirrhosis Clinical Trial using Tolvaptan

University of Florida - Recruiting 18 years to 70 years.
- Single Center, Open Labeled Pilot Study Evaluating the Safety and Efficacy of Tolvaptan in Patients With Cirrhotic Ascites.
Tolvaptan

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice.

Hepatitis B, Cirrhosis, or Awaiting Organ Transplant Clinical Trial using HBV vaccine

Fundaci¢n P£blica Andaluza para la gesti¢n de la Investigaci¢n en Sevilla - Recruiting 18 years to 65 years.
- Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation.
HBV vaccine

Non-Alcoholic Steatohepatitis (NASH) Clinical Trial using Simtuzumab 75 mg; Simtuzumab 125 mg; Placebo

Gilead Sciences - Recruiting 18 years to 60 years.
- A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety, and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2) in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).
Simtuzumab 75 mg; Simtuzumab 125 mg; Placebo

Confirmed Diagnosis of HCC;, Patients Who Are Scheduled to Underg Clinical Trial using TACE or Systemic Therapy

Chinese University of Hong Kong - Recruiting 18 years or older.
- A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Unresectable Hepatocellular Carcinoma.
TACE or Systemic Therapy

Hyponatremia Clinical Trial using Tolvaptan; Placebo; Hepatic Encephalopathy Assessment; Quality of Life Assessment; Vital signs; Blood laboratory tests; Ascites Evaluation; Edema

New York University School of Medicine - Recruiting 18 years or older.
- Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia.
Tolvaptan; Placebo; Hepatic Encephalopathy Assessment; Quality of Life Assessment; Vital signs; Blood laboratory tests; Ascites Evaluation; Edema

Acute Bleeding Esophageal Varices, or Liver Cirrhosis Clinical Trial using Hepatic venous pressure gradient measurement

Leiden University Medical Center - Recruiting 18 years to 75 years.
- A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy.
Hepatic venous pressure gradient measurement

Liver Cirrhosis Clinical Trial

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Recruiting 18 years to 75 years.
- Renal Function Determination With Creatinine and Cystatin C Dependent Formulas Compared to Gold Standard DTPA-TC-99 (Diethylene-triamine-pentaacetate- Technetium-99) in Mexican Cirrhotic Patients.

Liver Cirrhosis Clinical Trial using Placebo; Rifaximin SSD 40 mg IR tablet; Rifaximin SSD 80 mg IR tablet; Rifaximin SSD 40 mg SER tablet; Rifaximin SSD 80 mg SER tablet; Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet

Salix Pharmaceuticals - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis.
Placebo; Rifaximin SSD 40 mg IR tablet; Rifaximin SSD 80 mg IR tablet; Rifaximin SSD 40 mg SER tablet; Rifaximin SSD 80 mg SER tablet; Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet

Cirrhosis, Chronic Hepatitis C, Hepatitis C, or Hepatitis C, Chro Clinical Trial using Asunaprevir and Daclatsvir; Asunaprevir, daclatsvir, peginterferon, ribavirin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C.
Asunaprevir and Daclatsvir; Asunaprevir, daclatsvir, peginterferon, ribavirin

Biliary Liver Cirrhosis,, Hemochromatosis, Hepatitis, Hepatolenti Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Evaluation of Patients With Liver Disease.

Liver Cirrhosis Clinical Trial

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico - Recruiting 18 years to 65 years.
- Insulin Secretion and Sensitivity in Subjects With Liver Cirrhosis Undergoing Orthotopic Liver Transplantation (OLT): Pre- and Post-OLT Analysis.

Hepatitis C Clinical Trial using boceprevir; PegIFN-2b; RBV

Merck Sharp & Dohme Corp. - Recruiting 18 years to 75 years.
- A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105-00).
boceprevir; PegIFN-2b; RBV

Nonalcoholic Fatty Liver Disease Clinical Trial using MB12066 200mg; Placebo

KT&G Life Sciences Corp - Recruiting 20 years or older.
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis.
MB12066 200mg; Placebo

Unresectable Non-metastatic Hepatocellular Carcinoma, or Child A/ Clinical Trial using Zavedosr; Blood samples

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedosr): Phase I Study.
Zavedosr; Blood samples

Hepatitis C Virus Clinical Trial using ABT-450/r/ABT-267 plus Ribavirin

AbbVie - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Na‹ve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II).
ABT-450/r/ABT-267 plus Ribavirin

Refractory Ascites, Hepatic Hydrothorax, Hepatic Encephalopathy, Clinical Trial using Oral glutamine challenge; Psychometric Tests

University of Arkansas - Recruiting 18 years to 75 years.
- Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS).
Oral glutamine challenge; Psychometric Tests

Cirrhosis, Liver Fibrosis, Portal Hypertension, Cystic Fibrosis, Clinical Trial using Elastometry

Assistance Publique - H“pitaux de Paris - Recruiting 6 Months to 18 years.
- Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of FIBROSCANN..
Elastometry

Liver Cirrhosis, or Ascites Clinical Trial using Body composition in paracentesis

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Recruiting 18 years to 70 years.
- Body Composition Analysis in Cirrhotic Patients With Ascites Treated With Paracentesis.
Body composition in paracentesis

Hepatocellular Carcinoma, or Liver Cirrhosis Clinical Trial using Sirsphere trans-arterial radioembolization

Jules Bordet Institute - Recruiting 18 years or older.
- Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver.
Sirsphere trans-arterial radioembolization

Liver Cirrhosis, or Ascites Clinical Trial using ALFApump system

Sequana Medical AG - Recruiting 18 years or older.
- Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function in Patients With Cirrhosis and Recurrent or Refractory Ascites.
ALFApump system

Liver Cirrhosis Clinical Trial using entecavir; Thymosin-à

Beijing Friendship Hospital - Recruiting 18 years to 65 years.
- Optimized Treatment and Regression of HBV-induced Early Cirrhosis.
entecavir; Thymosin-à

Cirrhosis, Hepatic Encephalopathy, Diuretic-Resistant Refractory Clinical Trial using Large Volume Paracentesis

New York University School of Medicine - Recruiting 18 years to 75 years.
- The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis.
Large Volume Paracentesis

Cirrhosis Clinical Trial

Sir Ganga Ram Hospital - Recruiting 18 years to 75 years.
- A Prospective Validation of Child-Turcotte-Pugh-Kumar (CTPK) Score in Predicting Short Term Mortality in Patients With Liver Cirrhosis.

Cirrhosis, or Hepatorenal Syndrome Type I Clinical Trial using Terlipressin and albumin

Hospital Clinic of Barcelona - Recruiting 18 years or older.
- Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response.
Terlipressin and albumin

Decompensated Cirrhosis, Portal Hypertension, or Bleeding Varices Clinical Trial using 8-mm covered stent group; 10-mm covered stent group

Fourth Military Medical University - Recruiting 18 years to 75 years.
- The Effect of TIPS With 8- or 10-mm Covered Stent for Preventing Variceal Rebleeding in Cirrhotic Patients..
8-mm covered stent group; 10-mm covered stent group

Esophageal Varices, Bleeding, or Cirrhosis Clinical Trial using Stent; Tamponade

Hospital Clinic of Barcelona - Recruiting 18 years or older.
- EFFICACY AND SAFETY OF SELF-EXPANDING ESOPHAGEAL STENT VERSUS ESOPHAGEAL BALLOON TAMPONADE (SENGSTAKEN TUBE) AS A RESCUE THERAPY IN VARICEAL BLEEDING REFRACTORY TO MEDICAL AND ENDOSCOPIC TREATMENT. A MULTICENTRIC, RANDOMIZED CONTROLLED TRIAL..
Stent; Tamponade

Liver Cirrhosis, or Carcinoma, Hepatocellular Clinical Trial

Asan Medical Center - Recruiting 20 years to 80 years.
- Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver: Prospective Pathologic Correlation With Explanted Liver.

Cirrhosis, or Type 1 Hepatorenal Syndrome Clinical Trial using terlipressin given by intravenous boluses and albumin; terlipressin given by continuous intravenous infusion and albumin

University of Padova - Recruiting 18 years to 75 years.
- Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study..
terlipressin given by intravenous boluses and albumin; terlipressin given by continuous intravenous infusion and albumin

Hepatocellular Carcinoma, Liver Cirrhosis, Hepatitis B, or Hepati Clinical Trial using CE-US (SonazoidT); B-mode US

Japan Liver Oncology Group - Recruiting 20 years or older.
- Sonazoid Enhanced Liver Cancer Trial for Early Detection.
CE-US (SonazoidT); B-mode US

Liver Cirrhosis Clinical Trial using Plasma pheresis, Right portal vein embolization

Seoul National University Hospital - Recruiting 20 years to 70 years.
- Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy.
Plasma pheresis, Right portal vein embolization

Normal, Alcoholism, Cirrhosis, or Hepatitis C Clinical Trial using Ultrasound

Temple University - Recruiting 20 years to 70 years.
- Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound..
Ultrasound

Liver Cirrhosis Clinical Trial

National Taiwan University Hospital - Recruiting 50 years to 70 years.
- Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).

Liver Diseases, or Cirrhosis Clinical Trial using urotensin II

Bayside Health - Recruiting 18 years to 75 years.
- .
urotensin II

Biliary Cirrhosis, Primary Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 80 years.
- Family Studies in Primary Biliary Cirrhosis.

Hepatitis C, Hepatitis B, Autoimmune Hepatitis, Liver Cirrhosis, Clinical Trial

University Health Network, Toronto - Recruiting 18 years to 85 years.
- Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease.